Aller au contenu principal
2025 article

Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta‐Analysis With Reconstructed Time‐to‐Event and Trial Sequential Analysis

2Citations signalées, ce qui n’est pas une note de qualité
20Institutions déclarées
4Pays d’affiliation déclarés

Rattachement africain : us, Égypte, iq, es. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Ventricular tachycardia (VT) is a major contributor to sudden cardiac death among patients with ischemic heart disease (IHD). While catheter ablation reduces the arrhythmic burden, the impact on long-term outcomes remains uncertain. We assess the efficacy of catheter ablation in patients with IHD. METHODS: We performed a meta-analysis by systematically searching electronic databases from inception to April 2025. Pairwise, reconstructed time-to-event data meta-analyses and Trial Sequential analyses were conducted. RESULTS: A total of seven studies (1192 participants) were included. Among patients with IHD with ICD, VT ablation was associated with a significant reduction in ICD shocks (RR = 0.50, 95% CI = [0.34-0.74]), a trend toward reduced VT storm (RR = 0.64, 95% CI = [0.40-1.04], p = 0.07), and lower rates of cardiovascular hospitalization (RR = 0.73, 95% CI = [0.53-1.01], p = 0.06) compared to ICD alone. However, no significant differences were observed when compared to patients receiving ICD plus antiarrhythmic drugs (AADs). VT ablation showed no significant impact on mortality or VT/VF recurrence compared to either ICD alone or ICD with AADs. Reconstructed Kaplan-Meier analysis for all-cause mortality showed no significant difference between VT ablation and AAD + ICD. Trial Sequential Analysis provided conclusive evidence for VT/VF recurrence, while further data is required for other outcomes. CONCLUSION: Among patients with IHD with ICD, VT ablation reduces ICD shocks, VT storm, and cardiovascular hospitalizations compared to ICD-only therapy, but offers no significant advantage over ICD combined with AADs. VT ablation does not impact overall mortality or the recurrence of VT/VF. Trial sequential analysis confirmed conclusive evidence for VT/VF recurrence, while additional data is needed for other outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta‐Analysis With Reconstructed Time‐to‐Event and Trial Sequential Analysis
Date Crossref
16/09/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cardiac Arrhythmias and TreatmentsAtrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.